Trial Profile
An NRG Oncology/Gynecologic Oncology Group study of pegylated liposomal doxorubicin in combination with carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Bevacizumab; Carboplatin; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 04 Dec 2015 New trial record
- 23 Nov 2015 Results of dose-escalation phase (n=27) published in the Gynecologic Oncology